ZA201507309B - Markers of tumor cell response to anti-cancer therapy - Google Patents
Markers of tumor cell response to anti-cancer therapyInfo
- Publication number
- ZA201507309B ZA201507309B ZA2015/07309A ZA201507309A ZA201507309B ZA 201507309 B ZA201507309 B ZA 201507309B ZA 2015/07309 A ZA2015/07309 A ZA 2015/07309A ZA 201507309 A ZA201507309 A ZA 201507309A ZA 201507309 B ZA201507309 B ZA 201507309B
- Authority
- ZA
- South Africa
- Prior art keywords
- markers
- tumor cell
- cancer therapy
- cell response
- response
- Prior art date
Links
- 238000011319 anticancer therapy Methods 0.000 title 1
- 230000036755 cellular response Effects 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361812033P | 2013-04-15 | 2013-04-15 | |
| PCT/US2014/034217 WO2014172376A2 (en) | 2013-04-15 | 2014-04-15 | Markers of tumor cell response to anti-cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201507309B true ZA201507309B (en) | 2017-08-30 |
Family
ID=51686961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2015/07309A ZA201507309B (en) | 2013-04-15 | 2015-10-01 | Markers of tumor cell response to anti-cancer therapy |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023916B2 (enExample) |
| EP (1) | EP2986739B1 (enExample) |
| JP (1) | JP2016518124A (enExample) |
| KR (1) | KR20150140728A (enExample) |
| CN (1) | CN105308189B (enExample) |
| AU (1) | AU2014254091B2 (enExample) |
| BR (1) | BR112015026095A8 (enExample) |
| CA (1) | CA2909642A1 (enExample) |
| MX (1) | MX2015014486A (enExample) |
| MY (1) | MY180365A (enExample) |
| RU (1) | RU2664180C2 (enExample) |
| SG (2) | SG11201508058TA (enExample) |
| WO (1) | WO2014172376A2 (enExample) |
| ZA (1) | ZA201507309B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9510569B2 (en) | 2013-03-13 | 2016-12-06 | Regeneron Pharmaceuticals, Inc. | Genetically modified mouse with an inducible Acvr1 gene with a mutant R206H exon 5 that has ectopic bone formation |
| US10023916B2 (en) | 2013-04-15 | 2018-07-17 | Regeneron Pharmaceuticals, Inc. | Markers of tumor cell response to anti-cancer therapy |
| CN104388561A (zh) * | 2014-11-14 | 2015-03-04 | 浙江理工大学 | 肝癌生物标记物及其用途 |
| CN106636315B (zh) * | 2015-10-30 | 2020-06-02 | 益善生物技术股份有限公司 | 淋巴瘤相关microRNA检测试剂盒 |
| CN106636311B (zh) * | 2015-10-30 | 2020-06-02 | 益善生物技术股份有限公司 | 大肠癌相关microRNA检测试剂盒 |
| WO2017207623A1 (en) * | 2016-05-31 | 2017-12-07 | Université de Lausanne | Mirna as biomarkers and regulators of cancer stem cells |
| CN105950768A (zh) * | 2016-07-01 | 2016-09-21 | 江苏医诺万细胞诊疗有限公司 | 一种microRNA组合作为肿瘤标志物辅助诊断多种肿瘤的试剂盒及其检测方法 |
| CN106350582B (zh) * | 2016-08-25 | 2020-02-14 | 朱伟 | 一种与肺鳞癌辅助诊断相关的血清miRNA标志物及其应用 |
| CN106282360B (zh) * | 2016-08-31 | 2019-11-08 | 武汉博杰生物医学科技有限公司 | 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用 |
| CN107913284B (zh) * | 2016-10-09 | 2022-09-16 | 上海市东方医院 | miRNA302-367簇的微小RNA在靶向抑制血管新生和肿瘤生长的应用 |
| CN106778073B (zh) * | 2017-01-19 | 2019-09-06 | 北京吉因加科技有限公司 | 一种评估肿瘤负荷变化的方法和系统 |
| CN106834470A (zh) * | 2017-02-17 | 2017-06-13 | 张灏 | miRNA在制备癌症诊断试剂盒中的用途 |
| CN106676196B (zh) * | 2017-03-10 | 2019-05-07 | 上海核盾生物科技有限公司 | 一种用于诊断重度吸烟人群中肺鳞癌患者的非侵入性标记物及试剂盒 |
| CN107326092B (zh) * | 2017-08-25 | 2021-07-20 | 深圳市恩普电子技术有限公司 | 大肠癌相关的miRNA作为生物标志物的应用及大肠癌检测试剂盒 |
| CN107858427B (zh) * | 2017-10-24 | 2021-03-02 | 昆明理工大学 | miR-429在制备乳腺癌诊断和检测试剂盒中的应用 |
| CN108220381A (zh) * | 2017-12-07 | 2018-06-29 | 国家卫生计生委科学技术研究所 | 试剂在制备药物中的用途以及筛选药物的方法 |
| CN108531586B (zh) * | 2018-03-19 | 2022-03-29 | 朱伟 | 一种与乳腺癌辅助诊断相关的位于X染色体上的循环miRNA标志物及其应用 |
| CN109097473A (zh) * | 2018-08-24 | 2018-12-28 | 南京求臻基因科技有限公司 | 一种非小细胞肺癌辅助诊断试剂盒 |
| KR102256747B1 (ko) * | 2018-10-30 | 2021-05-25 | 가톨릭대학교 산학협력단 | 엑소좀 miR-125b를 포함하는 간암 전이 진단 또는 예측용 바이오마커 및 이의 용도 |
| US12257340B2 (en) | 2018-12-03 | 2025-03-25 | Agensys, Inc. | Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof |
| CN109593852B (zh) * | 2018-12-24 | 2022-03-08 | 朱伟 | 一种与鼻咽癌辅助诊断相关的血清miRNA标志物及其应用 |
| EP3969053A4 (en) * | 2019-05-15 | 2023-01-11 | The University of Chicago | LACTATE RESPONSE SYSTEM AND METHODS |
| CN110484620B (zh) * | 2019-08-09 | 2023-09-19 | 深圳市第二人民医院 | 生物标志物及其在制备诊断ptmc的产品中的应用 |
| WO2021108043A1 (en) | 2019-11-27 | 2021-06-03 | University Of Cincinnati | Assessing treatment response with estimated number of tumor cells |
| KR102293777B1 (ko) * | 2019-12-31 | 2021-08-25 | 연세대학교 산학협력단 | 신규한 UQCRB-관련 순환 miRNA 바이오 마커 및 이를 이용한 대장암의 진단 방법 |
| WO2021142088A1 (en) * | 2020-01-07 | 2021-07-15 | The Trustees Of The University Of Pennsylvania | Source specific exosomes for determining avoidance of cancer treatment and avoidance of checkpoint inhibitor therapies |
| CN113930505B (zh) * | 2020-03-30 | 2022-04-19 | 中国医学科学院肿瘤医院 | 用于肺癌诊断的试剂盒及装置 |
| CN111808950B (zh) * | 2020-06-02 | 2023-11-14 | 中南大学湘雅医院 | 一种甲状腺乳头状癌miRNA标志物及其应用 |
| CA3185666A1 (en) * | 2020-06-19 | 2021-12-23 | Agensys, Inc. | Markers for use in methods for treating cancers with antibody drug conjugates (adc) |
| CN111676291B (zh) * | 2020-07-14 | 2021-04-13 | 徐州医科大学 | 一种用于肺癌患病风险评估的miRNA标志物 |
| CN113025713B (zh) * | 2021-02-23 | 2022-11-22 | 浙江东睿生物科技有限公司 | 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用 |
| CN114150063B (zh) * | 2021-12-09 | 2024-12-17 | 觅瑞（杭州）生物科技有限公司 | 膀胱癌诊断用尿液miRNA标志物、诊断试剂及试剂盒 |
| CN115029347B (zh) * | 2022-05-11 | 2024-02-20 | 珠海中科先进技术研究院有限公司 | 识别和调控肝肾细胞纤维化的分子监测序列、重组质粒、抑制病毒 |
| WO2024006581A1 (en) * | 2022-07-01 | 2024-01-04 | City Of Hope | Biomarkers in colorectal cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2548394A1 (en) * | 2003-12-12 | 2005-06-30 | Bayer Pharmaceuticals Corporation | Methods for prediction and prognosis of cancer, and monitoring cancer therapy |
| JP5039544B2 (ja) * | 2004-06-18 | 2012-10-03 | ジェネンテック， インコーポレイテッド | 腫瘍の治療 |
| ES2343204T3 (es) | 2005-09-20 | 2010-07-26 | Scinopharm Singapore Pte, Ltd. | Formas cristalinas nuevas de hidrocloruro de irinotecan. |
| ES2442890T3 (es) | 2006-07-13 | 2014-02-14 | The Ohio State University Research Foundation | Métodos y composiciones basados en micro-ARN para el diagnóstico y el tratamiento de enfermedades relacionadas con el colon |
| US20100004253A1 (en) * | 2006-09-19 | 2010-01-07 | Novartis Ag | Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors |
| WO2008143795A1 (en) | 2007-05-11 | 2008-11-27 | Champions Biotechnology, Inc. | Human mesenchymal chrondrosarcoma xenograft model and its use in chemosensitivity testing |
| ES2600165T3 (es) * | 2008-02-28 | 2017-02-07 | The Ohio State University Research Foundation | Antagonistas de miR-32 para aumentar la respuesta del cáncer de próstata a la apoptosis |
| EP2334805A1 (en) * | 2008-06-04 | 2011-06-22 | Andor Pivarcsi | Skin cancer associated micrornas |
| JP2012509675A (ja) | 2008-11-25 | 2012-04-26 | ジェン−プロウブ インコーポレイテッド | 低分子ｒｎａを検出するための組成物および方法、ならびにその使用 |
| US20120231970A1 (en) | 2009-09-30 | 2012-09-13 | Japan Health Sciences Foundation | Colon cancer marker and method for testing for colon cancer |
| WO2011156777A1 (en) | 2010-06-10 | 2011-12-15 | Fred Hutchinson Cancer Research Center | Use of blood mir-210 for cancer prognosis |
| US20120264131A1 (en) | 2011-03-18 | 2012-10-18 | Baylor Research Institute | CHANGES IN THE EXPRESSION OF miR-200c/141 CLUSTER OF microRNAs AS BIOMARKERS FOR EPITHELIAL-TO-MESENCHYMAL TRANSITION IN HUMAN COLORECTAL CANCER METASTASIS |
| WO2012170711A1 (en) | 2011-06-07 | 2012-12-13 | Caris Life Sciences Luxembourg Holdings, S.A.R.L | Circulating biomarkers for cancer |
| WO2012174293A2 (en) | 2011-06-14 | 2012-12-20 | Nestec Sa | Methods for identifying inflammatory bowel disease patients with dysplasia or cancer |
| WO2014078850A1 (en) * | 2012-11-19 | 2014-05-22 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of cancer diagnosis, progression and response to therapy using a primary xenograft mouse model for cancer serum biomarker discovery |
| US10023916B2 (en) | 2013-04-15 | 2018-07-17 | Regeneron Pharmaceuticals, Inc. | Markers of tumor cell response to anti-cancer therapy |
-
2014
- 2014-04-15 US US14/253,592 patent/US10023916B2/en not_active Expired - Fee Related
- 2014-04-15 JP JP2016509033A patent/JP2016518124A/ja not_active Ceased
- 2014-04-15 SG SG11201508058TA patent/SG11201508058TA/en unknown
- 2014-04-15 MY MYPI2015703672A patent/MY180365A/en unknown
- 2014-04-15 SG SG10201708464TA patent/SG10201708464TA/en unknown
- 2014-04-15 WO PCT/US2014/034217 patent/WO2014172376A2/en not_active Ceased
- 2014-04-15 KR KR1020157031485A patent/KR20150140728A/ko not_active Ceased
- 2014-04-15 EP EP14784689.3A patent/EP2986739B1/en not_active Not-in-force
- 2014-04-15 BR BR112015026095A patent/BR112015026095A8/pt not_active Application Discontinuation
- 2014-04-15 MX MX2015014486A patent/MX2015014486A/es unknown
- 2014-04-15 RU RU2015148638A patent/RU2664180C2/ru not_active IP Right Cessation
- 2014-04-15 CA CA2909642A patent/CA2909642A1/en not_active Abandoned
- 2014-04-15 AU AU2014254091A patent/AU2014254091B2/en not_active Expired - Fee Related
- 2014-04-15 CN CN201480032378.8A patent/CN105308189B/zh not_active Expired - Fee Related
-
2015
- 2015-10-01 ZA ZA2015/07309A patent/ZA201507309B/en unknown
-
2018
- 2018-06-12 US US16/006,641 patent/US20180291468A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140308370A1 (en) | 2014-10-16 |
| WO2014172376A3 (en) | 2015-10-29 |
| MX2015014486A (es) | 2016-07-21 |
| AU2014254091A1 (en) | 2015-11-12 |
| AU2014254091B2 (en) | 2019-03-21 |
| BR112015026095A8 (pt) | 2020-01-21 |
| RU2015148638A (ru) | 2017-05-22 |
| SG11201508058TA (en) | 2015-10-29 |
| US10023916B2 (en) | 2018-07-17 |
| KR20150140728A (ko) | 2015-12-16 |
| JP2016518124A (ja) | 2016-06-23 |
| EP2986739A2 (en) | 2016-02-24 |
| SG10201708464TA (en) | 2017-11-29 |
| CN105308189B (zh) | 2018-09-04 |
| CA2909642A1 (en) | 2014-10-23 |
| US20180291468A1 (en) | 2018-10-11 |
| CN105308189A (zh) | 2016-02-03 |
| BR112015026095A2 (pt) | 2017-07-25 |
| EP2986739B1 (en) | 2018-04-04 |
| EP2986739A4 (en) | 2017-03-01 |
| MY180365A (en) | 2020-11-28 |
| RU2664180C2 (ru) | 2018-08-15 |
| HK1214630A1 (en) | 2016-07-29 |
| WO2014172376A2 (en) | 2014-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201507309B (en) | Markers of tumor cell response to anti-cancer therapy | |
| IL287516A (en) | Medicinal uses of empagliflozin | |
| IL241101B (en) | Medicinal uses of empagliflozin | |
| IL241102B (en) | Medicinal uses of empagliflozin | |
| EP3024456A4 (en) | Combinatorial methods to improve the therapeutic benefit of bisantrene | |
| IL241631B (en) | srm test for cancer treatment signal | |
| GB201322725D0 (en) | Cancer therapy | |
| LT2981271T (lt) | Empagliflozino terapinis panaudojimas | |
| SG11201509707QA (en) | Cancer therapy | |
| IL244453A0 (en) | Methods for determining response to medical treatment | |
| PT2978859T (pt) | Marcadores genéticos para previsão da capacidade de resposta à terapêutica | |
| SG11201507847UA (en) | Cancer therapy | |
| PT3060689T (pt) | Lixiviação de minerais | |
| EP3074771A4 (en) | Marker of cell death | |
| EP2961412A4 (en) | CANCER THERAPY | |
| GB2516028B8 (en) | Improved structure of shoe | |
| GB201518731D0 (en) | Tumour Therapy | |
| HK1226485A1 (en) | Methods of determining response to therapy | |
| GB201222952D0 (en) | Treatent of cancer | |
| GB201200262D0 (en) | Therapy of breast cancer | |
| AU2013904574A0 (en) | Marker of cell death | |
| GB201308365D0 (en) | Tumour therapy | |
| GB201320098D0 (en) | Psorias-Ease: Vitamin complex to ease psoriasis | |
| TWM475181U (en) | Structure of shoesole | |
| GB201317213D0 (en) | Cancer Therapy |